Program
RT-310
A development code. Also written as “RT-310 PK”.
Its studies are mostly in Prostatic Hyperplasia, led by Resurge Therapeutics.
Furthest: phase 2, since Nov 24, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Resurge Therapeutics | 33 open or running | phase 2since Nov 24, 2025 | Nov 9, 2023 | Dec 2028phase 2 · NCT07928206 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2023First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT06136819 · 20 enrolled · Australia, New Zealand
- Nov 24, 2025Phase 2 study in Prostatic HyperplasiaPhase 2 reachedNCT07264205 · 20 enrolled · Dominican Republic
- Oct 30, 2026Phase 2 study in Prostatic HyperplasiaNCT07928206 · 86 planned
Ahead
- Dec 2028Primary completion: phase 2 study in Prostatic HyperplasiaNCT07928206
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07928206Prostatic Hyperplasia | 2 | Not yet recruiting | Dec 2028 | 86 |
| NCT07264205Prostatic Hyperplasia · Dominican Republic | 2 | Active, not recruiting | Feb 26, 2026 | 20 |
| NCT06136819Prostatic Hyperplasia · Australia, New Zealand | 1 | Active, not recruiting | May 6, 2025 | 20 |
How it is read
Names in the registry
- “RT-310”, 3 entries
- “RT-310 PK”, 1 entry
Codes read as this program: RT310.
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.